Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide

Jon Mabley, Jignesh Patel, Abdelrahman Sayed, Roopen Arya, Greg Scutt

Research output: Contribution to journalLetterResearchpeer-review

Abstract

Anticoagulant therapy is commonly prescribed for both the acute treatment, and long-term prevention of venous thromboembolism (VTE), and as primary and secondary prevention of stroke in the context of atrial fibrillation (AF) [1]. Until recently the majority of patients requiring chronic anticoagulant therapy were prescribed vitamin K antagonists (VKA), as these were the only oral anticoagulant agents available [1]. A requirement for regular monitoring and VKA-drug or-food interactions has meant that not all patients that have an indication for anticoagulation have benefitted from these agents.
Original languageEnglish
Pages (from-to)36-38
Number of pages3
JournalThrombosis Research
Volume176
DOIs
Publication statusPublished - 12 Feb 2019

Fingerprint

Vasodilation
Anticoagulants
Nitric Oxide
Vitamin K
Food-Drug Interactions
Venous Thromboembolism
Primary Prevention
Secondary Prevention
Atrial Fibrillation
Therapeutics
Stroke

Keywords

  • Apixaban
  • Endothelial
  • Factor Xa inhibitors
  • Nitric oxide
  • Rivaroxaban
  • Vasodilation

Cite this

Mabley, Jon ; Patel, Jignesh ; Sayed, Abdelrahman ; Arya, Roopen ; Scutt, Greg. / Direct oral anticoagulant (DOAC)-mediated vasodilation : Role of nitric oxide. In: Thrombosis Research. 2019 ; Vol. 176. pp. 36-38.
@article{bced911b52464c0390476c361ddac382,
title = "Direct oral anticoagulant (DOAC)-mediated vasodilation: Role of nitric oxide",
abstract = "Anticoagulant therapy is commonly prescribed for both the acute treatment, and long-term prevention of venous thromboembolism (VTE), and as primary and secondary prevention of stroke in the context of atrial fibrillation (AF) [1]. Until recently the majority of patients requiring chronic anticoagulant therapy were prescribed vitamin K antagonists (VKA), as these were the only oral anticoagulant agents available [1]. A requirement for regular monitoring and VKA-drug or-food interactions has meant that not all patients that have an indication for anticoagulation have benefitted from these agents.",
keywords = "Apixaban, Endothelial, Factor Xa inhibitors, Nitric oxide, Rivaroxaban, Vasodilation",
author = "Jon Mabley and Jignesh Patel and Abdelrahman Sayed and Roopen Arya and Greg Scutt",
year = "2019",
month = "2",
day = "12",
doi = "10.1016/j.thromres.2019.02.014",
language = "English",
volume = "176",
pages = "36--38",
journal = "Thrombosis Research",
issn = "0049-3848",

}

Direct oral anticoagulant (DOAC)-mediated vasodilation : Role of nitric oxide. / Mabley, Jon; Patel, Jignesh; Sayed, Abdelrahman; Arya, Roopen; Scutt, Greg.

In: Thrombosis Research, Vol. 176, 12.02.2019, p. 36-38.

Research output: Contribution to journalLetterResearchpeer-review

TY - JOUR

T1 - Direct oral anticoagulant (DOAC)-mediated vasodilation

T2 - Thrombosis Research

AU - Mabley, Jon

AU - Patel, Jignesh

AU - Sayed, Abdelrahman

AU - Arya, Roopen

AU - Scutt, Greg

PY - 2019/2/12

Y1 - 2019/2/12

N2 - Anticoagulant therapy is commonly prescribed for both the acute treatment, and long-term prevention of venous thromboembolism (VTE), and as primary and secondary prevention of stroke in the context of atrial fibrillation (AF) [1]. Until recently the majority of patients requiring chronic anticoagulant therapy were prescribed vitamin K antagonists (VKA), as these were the only oral anticoagulant agents available [1]. A requirement for regular monitoring and VKA-drug or-food interactions has meant that not all patients that have an indication for anticoagulation have benefitted from these agents.

AB - Anticoagulant therapy is commonly prescribed for both the acute treatment, and long-term prevention of venous thromboembolism (VTE), and as primary and secondary prevention of stroke in the context of atrial fibrillation (AF) [1]. Until recently the majority of patients requiring chronic anticoagulant therapy were prescribed vitamin K antagonists (VKA), as these were the only oral anticoagulant agents available [1]. A requirement for regular monitoring and VKA-drug or-food interactions has meant that not all patients that have an indication for anticoagulation have benefitted from these agents.

KW - Apixaban

KW - Endothelial

KW - Factor Xa inhibitors

KW - Nitric oxide

KW - Rivaroxaban

KW - Vasodilation

UR - http://www.scopus.com/inward/record.url?scp=85061547013&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2019.02.014

DO - 10.1016/j.thromres.2019.02.014

M3 - Letter

VL - 176

SP - 36

EP - 38

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -